RU58841
| Nazwa produktu | RU58841 |
|---|---|
| Numer CAS | 154992-24-2 |
| Inne nazwy | PSK-3841; RU 58841; 4-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile |
| Wzór cząsteczkowy | C13H10F3N3O2 |
| Masa cząsteczkowa | 297.23 g/mol |
| Wygląd | Biały lub prawie biały krystaliczny proszek |
| Oznaczenie (HPLC) | ≥98,01 TP3T |
| Strata przy suszeniu | ≤0.5% |
| Metale ciężkie | ≤10 ppm |
| Rozpuszczalność | Soluble in DMSO, ethanol; slightly soluble in water |
| Opakowanie | 1 kg, 5 kg, 25 kg drums |
Potrzebujesz pomocy? Skontaktuj się z naszym zespołem

Synonimy: PSK-3841, RU 58841, 4-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile, RU-58841, 154992-24-2
RU58841 is a non-steroidal anti-androgen that has carved a niche in the research community for its topical activity against androgenetic alopecia and androgen-related skin conditions. Developed initially by Roussel Uclaf, this compound is a derivative of the topical anti-androgen flutamide, engineered to exert local effects without significant systemic absorption. It is available as a high-purity powder, typically ≥98% by HPLC, making it suitable for formulation and preclinical studies.
In the B2B arena, RU58841 is sought after by pharmaceutical and cosmetic ingredient buyers for its potential in hair care and dermatological products. Its mechanism involves competitive binding to the androgen receptor, thereby blocking dihydrotestosterone (DHT) from triggering follicle miniaturization. While not yet approved for clinical use, its profile continues to attract interest in the development of next-generation anti-hair loss solutions.
| Parametr | Specyfikacja |
|---|---|
| Wygląd | Biały lub prawie biały krystaliczny proszek |
| Oznaczenie (HPLC) | ≥98,01 TP3T |
| Strata przy suszeniu | ≤0.5% |
| Metale ciężkie | ≤10 ppm |
| Rozpuszczalność | Soluble in DMSO, ethanol; slightly soluble in water |
| Wielkość cząstek | NLT 98% through 80 mesh |
Room,5-0203, Unit 5, Beiyuanmen Street,Xi'an,Shaanxi,China